When was BlueSphere Bio founded?

BlueSphere Bio was founded in 2017 and raised its 1st funding round 3 years after it was founded.

Where is BlueSphere Bio located?

BlueSphere Bio is headquartered in Pittsburgh, United States. It is registered at 350 Technology Drive Suite 520 Pittsburgh, PA 15219.

How many employees does BlueSphere Bio have?

As of Aug 31, 2026, the latest employee count at BlueSphere Bio is 28.

Is BlueSphere Bio a funded company?

BlueSphere Bio is a funded company, having raised a total of $***** in its 1st and only funding round, a Series C round on Dec 29, 2020.

When was the latest funding round of BlueSphere Bio?

BlueSphere Bio's latest funding was a $***** Series C round on Dec 29, 2020, with participation from 0 investor.

Where does BlueSphere Bio rank among its competitors?

BlueSphere Bio ranks 1284th amongst 3464 active competitors, of which 1157 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of BlueSphere Bio?

BlueSphere Bio's top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

BlueSphere Bio - 2026 Company Profile, Team, Funding & Competitors

BlueSphere Bio is a series C company based in Pittsburgh (United States), founded in 2017 by David Apelian. It operates as a Developer of T-cell therapies to treat cancer. BlueSphere Bio has raised $45.6M in funding. The company has 3464 active competitors, including 1157 funded and 808 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.

Company Details

Developer of T-cell therapies to treat cancer. The company has developed its proprietary TCXpress technology which uses the patient’s own immune system to attack their cancer specifically. It provides personalized T cell treatments to eradicate cancer.

Website: bluespherebio.com
Email ID: *****@bluespherebio.com
Registered Address: 350 Technology Drive Suite 520 Pittsburgh, PA 15219

Key Metrics

Founded Year

2017

Location

Pittsburgh, United States

Stage

Series C

Total Funding

$45.6M in 1 round

Latest Funding Round

Series C, Dec 29, 2020, $*****

Ranked

1284^th among 3464 active competitors

Employee Count

28 as on Aug 31, 2026

Similar Companies

Jazz Pharmaceuticals & 3171 more

View BlueSphere Bio's full profile

BlueSphere Bio is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
BLUESPHERE BIO, INC. CIN: 82-4979766 , United States, Active	Nov 12, 2017	-	21 (As on Dec 31, 2020)	-

BlueSphere Bio has raised a total funding of $45.6M over 1 round.

Here is the list of recent funding rounds of BlueSphere Bio:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 29, 2020	1663084	Series C	8403388	3602674	9517584	7656717

Access funding benchmarks and valuations. Sign up today!

View details of BlueSphere Bio's funding rounds and investors

The founders of BlueSphere Bio is David Apelian.

Here are the details of BlueSphere Bio's key team members:

David Apelian: Co-Founder of BlueSphere Bio.

View details of BlueSphere Bio's Founder profiles and Board Members

BlueSphere Bio's employee count trend

BlueSphere Bio has 28 employees as of Aug 26. Here is BlueSphere Bio's employee count trend over the years:

Uncover BlueSphere Bio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of BlueSphere Bio include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of BlueSphere Bio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Leaps by Bayer, New Enterprise Associates ... & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
9th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	72/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
1284th	BlueSphere Bio 2017, Pittsburgh (United States), Series C	Developer of T-cell therapies to treat cancer	$45.6M	-	35/100